hotspot -WSS

hotspot

author：leisure time 2025-10-02 22:56:48 - browse：972

Verve Therapeutics CEO Sekar Kathiresan Verve

SAN FRANCISCO — The promise of genome editing has given rise to potentially curative medicines for rare, life-threatening diseases that generally affect small numbers of patients. But since Verve Therapeutics was founded in 2018, it’s had a wider aperture: using the molecular tools of genome editing to go after the most common cause of death in the world.

The plan, according to Verve CEO Sekar Kathiresan, is to edit out heart attacks for the millions of people at risk for severe cardiovascular disease. It’s a goal that’s more than a little audacious. There’s just one approved genome editing medicine, a treatment for sickle cell disease, and it only passed Food and Drug Administration review last month. Base editing, the CRISPR successor Verve uses to conduct its molecular surgery, is only a few years old.

“When we started, there were so many things that we were kind of going against the grain on,” Kathiresan told STAT at the J.P. Morgan Healthcare Conference in San Francisco this week. “In 2018, it was all about platforms, not about specific diseases and products, or taking this kind of idea for a large indication as opposed to cancer or rare disease. But we’ve always been motivated by a deep conviction in one simple research insight, which is that if your blood cholesterol is really low, lifelong, it is very hard to get a heart attack.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Wildfire smoke exposes gaps in outdoor worker protections
Next article： 'Make People Better': The CRISPR babies story you probably don't know

hotspot

WSS

H5N1 virus can be tracked in retail milk, scientists say

'Make People Better': The CRISPR babies story you probably don't know

Questions and answers about ramping up H5N1 bird flu vaccine

Cue Health, Covid

Humana sues Biden admin over Medicare Advantage audit rule

Bird flu surveillance in wastewater gets boost from consortium

focus

hotspot

entertainment

Continuity nursing helped my family in our darkest PICU moments

Questions and answers about ramping up H5N1 bird flu vaccine

In age of alternative facts, a scholarly course on calling out crap

UnitedHealth argues against case alleging wrongful AI care denials

Dobbs anniversary: the lost opportunity of abortion as health care

Listen: Biogen's potential pivot, & Illumina's next chapter

Medical records are filled with copy

FDA poised to publish guidelines for clinical trial diversity

23andMe had bad news about my health. I wish a person had delivered it

Illumina names Agilent executive as new CEO

leisure time

As a primary care physician, here's how I hope to partner with AI

Questions and answers about ramping up H5N1 bird flu vaccine

Snackable artificial intelligence, expert AI, and the pharma industry

For longer

Addressing health care workers' trauma can help fight burnout

What drug price negotiations mean for Medicare Part D

hotspot

knowledge

leisure time

focus